U.S. Markets close in 2 hrs 44 mins

Abiomed (ABMD) Looks Good: Stock Adds 7.5% in Session

Zacks Equity Research

Abiomed, Inc. ABMD was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $168.78 to $181.07 in the past one-month time frame.

The company has seen a mixed track record when it comes to estimate revisions of four increases and two decreases over the past one month, while the Zacks Consensus Estimate has moved higher, suggesting that more solid trading could be ahead for Abiomed. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Abiomed currently has a Zacks Rank #2 (Buy), while its Earnings ESP is positive.

ABIOMED, Inc. Price

ABIOMED, Inc. Price | ABIOMED, Inc. Quote

Another stock worth considering in the Medical - Instruments industry is Luminex Corporation LMNX, which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ABMD going up? Or down? Predict to see what others think: Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Luminex Corporation (LMNX) : Free Stock Analysis Report
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research